MARKET

CLSN

CLSN

Celsion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.060
-0.130
-10.92%
After Hours: 1.100 +0.04 +3.77% 19:59 04/16 EDT
OPEN
1.160
PREV CLOSE
1.190
HIGH
1.173
LOW
1.020
VOLUME
4.38M
TURNOVER
--
52 WEEK HIGH
6.50
52 WEEK LOW
0.4305
MARKET CAP
91.75M
P/E (TTM)
-1.5351
1D
5D
1M
3M
1Y
5Y
Celsion Corporation closes stock offering
Celsion Corporation (CLSN) has closed the previously announced registered direct offering of 11.5M shares of common stock at a purchase price of $1.30 apiece.The net proceeds have reached $13.9M after
Seekingalpha · 04/07 13:09
Best Penny Stocks To Buy Right Now? 5 Biotech Stocks For Your List
Penny Stocks · 04/07 11:41
CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING
Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company"), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purchase price of $1.30 per share, resulting in net proceeds of $1...
GlobeNewswire · 04/05 21:00
8-K: Celsion CORP
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) -- Pursuant to Section 13 or 15(d) of...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/02 23:46
Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates
Benzinga · 04/01 13:23
Celsion Says Poster On Co's Phase I/II OVATION 2 Study Presented At Society Of Gynecologic Oncology Virtual Annual Meeting On Women's Canver
Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a poster highlighting the Company's ongoing Phase I/II OVATION 2
Benzinga · 04/01 12:36
Poster on Celsion Corporation's Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer
Company reports further strengthening of R0 resection results in patients treated with GEN-1
GlobeNewswire · 04/01 12:30
CHPT, RMO, SUNW and CLSN among midday movers
Gainers: Wah Fu Education (WAFU) +74%.Liquid Media (YVR) +25%.Conn's (CONN) +23%.FreightCar America (RAIL) +23%.Greenlane (GNLN) +22%.Arcadia Biosciences (RKDA) +20%.SunLink Health Systems (SSY) +19%.Sunworks (SUNW) +18%.Scienjoy (SJ) +18%.Chargepoint (CHP...
Seekingalpha · 03/31 16:51
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLSN. Analyze the recent business situations of Celsion through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLSN stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 3.23M
% Owned: 3.73%
Shares Outstanding: 86.56M
TypeInstitutionsShares
Increased
8
193.32K
New
3
133.38K
Decreased
7
939.91K
Sold Out
14
1.32M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chief Financial Officer/Senior Vice President/Secretary/IR Contact Officer
Jeffrey Church
Executive Vice President
Khursheed Anwer
Senior Vice President
Nicholas Borys
Director/Chief Executive Officer/President/Chairman
Michael Tardugno
Independent Director
Donald Braun
Independent Director
Pok Yu Chow
Independent Director
Frederick Fritz
Independent Director
Robert Hooper
Independent Director
Andreas Voss
No Data
About CLSN
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Webull offers kinds of Celsion Corporation stock information, including NASDAQ:CLSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSN stock methods without spending real money on the virtual paper trading platform.